HLA-A*02:01-restricted Preferentially Expressed Antigen in Melanoma (PRAME) peptide complex (HLA-A*02:01/PRAME)

The HLA-A*02:01-restricted PRAME-derived peptide complex is a prominent target in the field of cancer immunotherapy, specifically for T-cell receptor (TCR)-based interventions [1]. PRAME (Preferentially Expressed Antigen in Melanoma) is a cancer-testis antigen that is highly expressed in a wide range of solid and hematological malignancies but has very limited expression in normal adult tissues, primarily the testis and ovaries [2]. The specific peptide sequence, most commonly the SLLMWITQC epitope, is processed and presented on the cell surface by the HLA-A*02:01 allele, which is one of the most prevalent MHC class I molecules in human populations [3]. This peptide-MHC (pMHC) complex serves as a "flag" for the immune system, allowing engineered TCR-T cells or bispecific T-cell engagers to identify and destroy malignant cells [4]. Therapeutic strategies targeting this complex, such as ImmTACs (Immune mobilizing monoclonal TCRs against cancer) and TCR-engineered T-cells, are currently in clinical trials for various indications including melanoma and lung cancer [5]. The high specificity of the PRAME-A2 complex makes it an attractive candidate for reducing off-target effects while maximizing anti-tumor efficacy [6].

Other names

PRAME SLLMWITQC peptideHLA-A2/PRAME complexPRAME-A2PRAME-derived peptide-MHC complex

T-cell receptor (TCR) mediated recognition and subsequent T-cell directed lysis of tumor cells.